Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myocor receives approval for heart device study
The single-arm feasibility study is designed to evaluate the safety and feasibility of the percutaneously implanted iCoapsys system in treating patients with mitral valve insufficiency caused by left
The single-arm feasibility study is designed to evaluate the safety and feasibility of the percutaneously implanted iCoapsys system in treating patients with mitral valve insufficiency caused by left
The present work performed under a co-operative research and development agreement with the department of veteran’s affairs demonstrated that inhibition of the enzyme protein kinase C-iota is a
The parties are collaborating on the development of products via a joint committee. Research and development funding will initially be the responsibility of Actelion. The two companies will
The experimental, trivalent vaccine consists of the co-administration of two live-attenuated bacteria, the Peru-15pCTB vaccine candidate that forms the basis of Avant’s investigational combination ETEC/cholera vaccine, and Avant’s
Pro-Pharmaceuticals engages in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases, and viral infections. Anatole Klyosov,chief
In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction
The pharmaceutical and biotechnology industries will now have access to dedicated, focused scientific expertise in the drug development spectrum from discovery and preclinical through IND into Phase I
Under the terms of the settlement agreement, Novartis has granted Watson a license to its US patents covering Exelon for a generic version of the drug. The agreement
The Phase IIb, randomized, double-blind, placebo-controlled clinical trial, named SeaGen Mariner, is expected to enroll approximately 200 relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients at more
The biologics license application (BLA) submission relies on data from two pivotal Phase III studies performed in the US and abroad totalling 252 patients followed-up for up to